ACVR2A

Across TCGA pan-cancer cohorts, ACVR2A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ACVR2A’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ACVR2A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ACVR2A is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

PDAC, LUAD, and LSCC are the cancer types where ACVR2A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACVR2A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	+1.352	<.001	8	view →
LUAD	All	II,III,IV	−0.567	.016	3	view →
LSCC	All	II,III,IV	−0.421	.002	2	view →
HNSC	All	III,IV	−0.522	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ACVR2A–PDAC

Open the PDAC breakdown →